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Lower risk of smoking-related 
cancer in individuals with familial 
hypercholesterolemia compared 
with controls: a prospective 
matched cohort study
Henriette W. Krogh1,7*, Karianne Svendsen1,2,7*, Jannicke igland3,6, Liv J. Mundal1,2, 
Kirsten B. Holven1,4, Martin P. Bogsrud4,5, Trond P. Leren5 & Kjetil Retterstøl1,2
According to guidelines, individuals with familial hypercholesterolemia (FH) shall receive lifestyle 
intervention and intensive lipid-lowering treatment from early in life to reduce the risk of coronary 
heart disease. Our aim was to study if treatment of FH also could affect risk of lifestyle-related cancer. 
We presented cumulative incidence of total cancer and lifestyle-related cancer sites in individuals with 
genetically verified FH (n = 5531) compared with age and sex matched controls (n = 108354). Individuals 
with FH had 20% lower risk of smoking-related cancer compared with the control population [HR 0.80 
(95% CI, 0.65–0.98)], in particular men with FH at 40–69 years at age of diagnosis with HR 0.69 (95% CI,  
0.49–0.97). The FH population and controls had similar rates of total cancer [HR 0.97 (95% CI, 0.86–1.09)], 
cancer related to poor diet [HR 0.82 (95% CI, 0.59–1.15)], cancer related to physical inactivity [HR 0.93 
(95% CI, 0.73–1.18)], alcohol-related cancer [HR 0.98 (95% CI, 0.80–1.22)] and cancer related to obesity 
[HR 1.03 (95% CI, 0.89–1.21)]. In summary, we found reduced risk of smoking-related cancer in individuals 
with FH, most likely due to a lower prevalence of smoking. Implications of these findings can be increased 
motivation and thus compliance to treatment of hypercholesterolemia.
A combination of lifestyle intervention including dietary advice, physical activity, smoking cessation and 
lipid-lowering medication, usually statins, is vital in the treatment of hypercholesterolemia1. Familial hypercho-
lesterolemia (FH) is a disorder usually caused by a mutation in the low density lipoprotein (LDL) receptor gene, 
causing elevated plasma levels of LDL cholesterol (LDL-C) which leads to increased risk of coronary heart dis-
ease (CHD)2. Individuals with FH are therefore recommended lifelong lifestyle intervention and lipid-lowering 
medication from the age of 8–10 years or from the time of diagnosis3. Consequently, it has been demonstrated 
that both children and adults with FH have a healthier lifestyle than controls4,5. Cardiovascular disease (CVD) 
and cancer are the two main types of non-communicable diseases (NCDs). These diseases share several risk fac-
tors such as tobacco use, an unhealthy diet including low fruit and vegetable intake, lack of physical activity, and 
alcohol use6. Accordingly, lifestyle advice to prevent CVD and cancer overlap6. In the present study, we therefore 
investigated whether treatment for FH results in lower risk of total and lifestyle-related cancer in people with FH 
compared with an age and sex matched control population.
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Materials and Methods
Study design and population. This study is a prospective matched cohort study comprising of a sample of 
individuals with genetically verified FH, and age and sex matched controls (1:20). The FH sample was obtained 
from the Unit for Cardiac and Cardiovascular Genetics (UCCG) Registry for individuals with genotyped FH, at 
Oslo University Hospital. The UCCG Registry has been described elsewhere7,8. In brief, since its establishment in 
1992 all individuals with genetically verified FH are asked for consent to be included in the registry. The UCCG 
Registry currently holds 8511 individuals with genetically verified FH9. In the present study, birth year, sex, and 
date and age at inclusion to the registry were extracted from the UCCG Registry. Inclusion date to the registry 
was equal to date of genetic diagnosis after 1.1.1992. In total 744 individuals were missing exact inclusion date due 
to diagnosis prior to 1992 and were assigned inclusion date 1.1.1992. In this study we included 5645 individuals 
with FH who were registered between 1.1.1992 and 1.3.2014 (deadline of study reservation). The FH population 
was matched on age and sex on inclusion date to the UCCG Registry, to 112907 controls randomly drawn from 
the Population Registry of Norway. After excluding subjects for various reasons, as shown in Fig. 1, we analysed a 
cohort of 5521 individuals with FH and 108151 age and sex matched controls for their first cancer event or death 
from cancer in the period from baseline (date of inclusion to the registry) and until latest 31.12.2017 (last day of 
registry coupling) (Fig. 1).
This study was approved by The Regional Committee of Medical and Health Research Ethics for South-Eastern 
Norway (reference 2011/1343 REK Sør-Øst B), by the Norwegian Data Protection Official at Oslo University 
Hospital, and complies with the Declaration of Helsinki. Due to the nature of this study, we were granted exemp-
tion from the obligation to gain informed consent from the FH population and controls. However, the individuals 
with FH were informed about the study by a letter of information and were given the opportunity to reject having 
their information linked to the registries, as previously described7,10.
cancer outcomes. The FH population and controls were linked (by means of the 11-digit personal identifi-
cation number unique to each Norwegian resident) to the Cancer Registry of Norway (CRN) and the Norwegian 
Cause of Death Registry (NCoDR) in order to obtain information on cancer incidence and mortality (underlying 
cause of death in the death certificates). Endpoints were defined according to the International Classification of 
Diseases (ICD), version 10 (ICD-10) and for NCoDR also ICD-9 (1992–1995) codes. All ICD-9 codes were con-
verted to the ICD-10 codes that are shown in Table 1.
As stated earlier, CVD and cancer have several lifestyle-related risk factors in common6. We identified and 
categorized cancer types according to World Cancer Research Fund (WCRF) & American Institute for Cancer 
Research (AIRC) and Cancer Facts & Figures from the American Cancer Society (ACS) who have defined groups 
of lifestyle-related cancers11,12. Risk factors that according to WCRF&AICR and ACS have sufficient or strong 
(either convincing or probable) evidence for causing cancer in humans were included in the study11,12. Hence, the 
lifestyle-related cancer sites included smoking-related cancer11, cancer related to poor diet [red and processed 
meat consumption, low dietary fiber and wholegrain consumption, and low dietary calcium consumption], can-
cer related to physical inactivity, alcohol-related cancer, and cancer related to body fatness and weight gain12, as 
shown with corresponding ICD-10 codes in Table 1.
Statistical analysis. Baseline for start of follow-up was defined as date of the pathogenic genetic diagno-
sis for individuals with FH, and the same date was chosen for each of the FH patients’ corresponding controls. 
Figure 1. Flow chart of individuals with familial hypercholesterolemia (FH) and age and sex matched controls 
included in the study.
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Follow-up time was calculated as time from baseline until date of cancer diagnosis or death (from CRN or 
NCoDR), or 31.12.2017, whichever came first. Cumulative incidence curves for risk of cancer with death treated 
as competing event were constructed separately for the FH population and the control population using the 
stcompet-package in Stata. The curves are presented graphically with age as the time scale. Risk of cancer among 
individuals with FH was compared with age and sex matched controls in terms of hazard ratios (HR) with 95% 
confidence intervals (95% CI) obtained from Cox proportional hazards regression, stratified on matched risk set 
to take the matching into account. Because of the already known increased risk of CVD in the FH population7, 
we also performed competing risk regression with deaths treated as competing event in order to take into account 
that individuals with FH might die from CVD before they get cancer. The results were however very similar (only 
a small change in the second decimal of HRs) and we therefore only present results from Cox regression. Because 
lifestyle advice may affect women and men differently, and because age at time of FH diagnosis also may modify 
the risk of cancer, we performed analyses stratified on sex and age groups (0–39, 40–69 and age 70+). All analyses 
were performed with Stata version 15 and 5% was used as the significance level for all statistical tests.
Results
Incidence of total cancer and grouped lifestyle-related cancers for the FH population and the control population 
are summarized in Table 1. Baseline characteristics of the study populations are shown in Table 2. Age at baseline 
corresponds to age at genetic FH diagnosis for the majority of the sample and was 33.7 ± 18.9 in the FH popula-
tion (n = 5521) and 33.2 ± 18.7 in the age and sex matched controls (n = 108151) (Table 2).
total cancer. A total of 289 cancer cases were observed in the FH population and 5579 cases in the control 
population (Table 1). In the FH population, the total number of person years of follow-up was 71253 and the 
median time to cancer diagnosis among those who developed cancer was 8.7 years. In the control population, 
the corresponding numbers were 1366647 person years and 8.8 years, respectively. As illustrated in Fig. 2A, the 
cumulative incidence curve for total cancer increased with age, similarly for the FH population and controls. The 
total incidence per thousand person years of follow-up was 3.99 (95% CI, 3.88–4.09) in the control population 
and 4.06 (95% CI, 3.61–4.55) in the FH population. The HR for incidence of total cancer for the FH population 
versus the control population was 0.97 (95% CI, 0.86–1.09) (Table 1). Similarly, there was no significant difference 
in total cancer between the FH population and controls stratified by men [HR 0.97 (95% CI, 0.82–1.15)] and 
women [HR 0.98 (95% CI, 0.83–1.15)], nor for any of the three age groups (0–39, 40–69 and age 70 + at baseline) 
(Table 3).
Lifestyle-related cancer. In the FH population, we observed 97 cases of smoking-related cancer, whereas 
2220 cases were observed in the control population. Individuals with FH had 20% lower risk of smoking-related 
cancer compared with the control population [HR 0.80 (95% CI, 0.65–0.98)]. In the age group 40–69 years 
at baseline, the FH population was 27% less likely to have smoking-related cancer compared with controls, 
as demonstrated with a HR of 0.73 (95% CI, 0.57–0.94). The strongest relative reduced risk was observed for 
men with FH aged 40–69 years at baseline, where an incidence rate per thousand person years of follow-up for 
smoking-related cancer was 3.94 (95% CI, 3.69–4.20) compared with 2.85 (95% CI, 2.04–3.99) for controls [HR 
0.69 (95% CI, 0.49–0.97]. The corresponding HR for women aged 40–69 years was 0.79 (95% CI, 0.56–1.13) 
(Table 4 and Fig. 2B).
Cancer types grouped by risk factors Description ICD-10 codesa FH (n) Controls (n) HR (95%CI)
Total cancer All cancers C00-C99 289 5579 0.97 (0.86–1.09)
Smoking-related cancer*
Cancer types known to be associated with smoking, including 
mouth, pharynx, larynx, lung, esophagus, stomach, liver, pancreas, 
colorectum, kidney, renal pelvis, bladder, uterine cervix, and acute 
myeloid leukemia
C00-C16, C18-C22, C25, 
C26.0, C30-C34, C53, 
C64-C66, C67, C92.0
97 2220 0.80 (0.65–0.98)
Cancer related to poor dietb,** Cancer types known to be associated with a poor diet, including colorectal and stomach C16, C18-C21 36 801 0.82 (0.60–1.15)
Cancer related to physical inactivity** Cancer types known to be associated with lack of physical activity, including colorectumc, breast, and endometrium
C18-C19, C26.0, C50, 
C54-C55 72 1455 0.93 (0.73–1.18)
Alcohol-related cancer**
Cancer types known to be associated with alcohol intake, including 
mouth, pharynx, larynx, esophagusd, stomach, liver, colorectum, 
and breast
C00-C15, C18-C22, C26.0, 
C32, C50 90 1718 0.98 (0.80–1.22)
Cancer related to body fatness and 
weight gain**
Cancer types known to be associated with excess body weight, 
including mouth, pharynx, larynx, esophaguse, stomachf, liver, 
gallbladder, pancreas, colorectum, kidney, breast, endometrium, 
ovary, and prostateg
C00-C15, C16.0, C18-C25, 
C26.0, C32, C50, C54-C56, 
C61, C64
172 3131 1.03 (0.89–1.21)
Table 1. Definition and categorization of total and lifestyle-related cancer sites, number of cases and hazard 
ratios for FH women and men combined compared with the matched control population. *Source: Cancer 
Facts & Figures 2018, American Society of Cancer. **Source: The 2018 Third Expert Report, World Cancer 
Research Fund/American Institute for Cancer Research. aOrigin of the tumor. Converted based on localization 
codes and morphology codes, and designated as the ICD-10 group (or converted from ICD-9), bPoor diet = Red 
and processed meat consumption, low dietary fiber and wholegrain consumption, and low dietary calcium 
consumption, cColon only, dSquamous cell carcinoma only, eAdenoncarcinoma, fCardia only, gAdvanced 
prostate cancer. FH, familial hypercholesterolemia; n, number of cases; HR, hazard ratio, CI, confidence 
interval. 
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Our matched analysis further showed that the HR for cancer related to poor diet, for women and men com-
bined, was 0.82 (95% CI, 0.60–1.15) (Table 1). There were 14 incidence cases of cancer related to poor diet for 
women with FH and 434 for the female control population resulting in HR of 0.59 (95% CI, 0.35–1.01). The cor-
responding HR for men was 1.10 (95% CI, 0.71–1.69) (Supplementary Table 1). There were no difference in risk 
estimates between the total FH population and controls for cancer related to physical inactivity [HR 0.93 (95% CI, 
0.73–1.18)], alcohol-related cancer [HR 0.98 (95% CI, 0.80–1.22)] and cancer related to body fatness and weight 
gain [HR 1.03 (95% CI, 0.89–1.21)] (Table 1). Neither were there any differences when the populations were strat-
ified by sex and age groups (Supplementary Tables 2–4).
Total Control FH
n 113672 108151 5521
Sex, n (%)
   Women 58397 (51.4) 55547 (51.4) 2850 (51.6)
   Men 55275 (48.6) 52604 (48.6) 2671 (48.4)
   Age, mean (sd)* 33.2 (18.7) 33.2 (18.7) 33.7 (18.9)
Table 2. Baseline characteristics of the study population. *Age at FH diagnosis. FH, familial 
hypercholesterolemia; n, number of cases; sd, standard deviation.
Figure 2. (A,B) Cumulative incidence curve for total cancer (A) and smoking-related cancer (B) in individuals 
with familial hypercholesterolemia (FH) compared with matched controls, stratified on sex and age (inclusion 
to the UCCG Registry) as the time scale.
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Discussion
We found that a FH mutation was associated with 20% reduced risk of smoking-related cancer but no reduced 
risk of total cancer after a median of 8.7 years of follow-up. The results suggest that treatment of FH, intended to 
reduce the risk of CVD may also reduce the risk of cancer.
We have previously shown that cancer mortality in individuals with FH is similar to that of the general 
Norwegian population13. The current data including non-fatal cases with almost eight times more events and 
a matched control population supports and extends our previous findings. Importantly, the significant reduced 
risk of smoking-related cancer in FH is in agreement with results from the Simon Broome Register reporting 
reduced risk of fatal cancer [standardized mortality ratio of 0.70 (95% CI, 0.59–0.83)] mainly due to lower risk of 
smoking-related cancers such as respiratory and lymphatic cancer14,15.
Lung cancer, one of the largest contributors to smoking-related cancer, is among the most common cancer 
sites in Norway particularly in men16,17. Our results show that men with FH aged 40–69 years at baseline had 
a 31% lower risk of smoking-related cancer than their matched non-FH controls. The ACS consider smoking 
a strong risk factor for the cancer sites included in the predefined group of smoking-related cancers11. Hence, 
the reduced risk observed in the FH group is likely caused by less smoking in FH individuals than in controls. 
Indeed, in 2014–15, 9% of a subsample of the FH population in the present study were current smokers18, com-
pared with 13% of the general population19 and similar differences are supported by others20. Furthermore, the 
SAFEHEART study reported that 2404 adult individuals with FH smoked less than their non-affected siblings5. 
Neil and co-workers also proposed that a reduced cancer mortality in FH might be attributable to the effects of 
regular medical control, including being given early and continuous lifestyle advice from early in life, resulting 
in better prognosis14,15.
Yet, in this study the incidences of cancer related to poor diet or physical inactivity were not significantly 
reduced in the FH population, except a tendency towards a reduced risk of cancer related to poor diet in women 
with FH compared with controls, with a HR of 0.59 (95% CI, 0.35–1.01). By further investigating the risk of only 
colorectal cancer, which accounts for the majority of cancer incidents related to poor diet in the Norwegian popu-
lation, we found a HR of 0.55 (95% CI, 0.31–0.98) in FH women compared with controls (n = 12/2850 for FH and 
n = 400/55547 for controls, respectively). Colorectal cancer is the second most frequent cancer site in Norwegian 
women16. However, these results of post hoc analyses and small numbers should be interpreted with caution and 
more information on risk factors of colorectal cancer is warranted. We cannot rule out the possibility that the FH 
mutation per se can protect against cancer, but this is less plausible from a current biological point of view.
Total study population Women Men
Cases HR (95% CI)* p-value Cases HR (95% CI)* Cases HR (95% CI)*
Age 0–39
   Control 923 1 589 1 334 1
   FH 50 1.09 (0.82–1.44) 0.57 28 0.95 (0.65–1.39) 22 1.33 (0.87–2.05)
Age 40–69
   Control 4050 1 1962 1 2088 1
   FH 203 0.95 (0.82–1.09) 0.44 100 0.98 (0.80–1.20) 103 0.91 (0.75–1.11)
Age 70+
   Control 606 1 337 1 269 1
   FH 36 0.98 (0.70–1.37) 0.90 20 0.99 (0.63–1.57) 16 0.96 (0.58–1.60)
Table 3. Cases of total cancer and hazard ratios for the FH population compared with the control population, 
with stratification on age at baseline. *HR from Cox proportional hazards regression stratified on matched case 
set. FH, familial hypercholesterolemia; HR, hazard ratio; CI, confidence interval.
Total study population Women Men
Cases HR (95% CI)* p-value Cases HR (95% CI)* Cases HR (95% CI)*
Age 0–39
   Control 262 1 153 1 109 1
   FH 14 1.07 (0.62–1.83) 0.82 5 0.66 (0.27–1.60) 9 1.63 (0.83–3.22)
Age 40–69
   Control 1673 1 769 1 904 1
   FH 66 0.73 (0.57–0.94) 0.01 32 0.79 (0.56–1.13) 34 0.69 (0.49–0.97)
Age 70+
   Control 285 1 163 1 122 1
   FH 17 0.95 (0.58–1.56) 0.85 9 0.90 (0.46–1.77) 8 1.02 (0.50–2.09)
Table 4. Cases of smoking-related cancer and hazard ratios for the FH population compared with the control 
population, with stratification on age at baseline. *HR from Cox proportional hazards regression stratified on 
matched case set. FH, familial hypercholesterolemia; HR, hazard ratio; CI, confidence interval.
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There was no difference in incidence of alcohol-related cancer, nor cancer related to body fatness and weight 
gain, between the FH population and the matched controls. In the present study, the mean age at genetic diag-
nosis and assumed initiation of lifestyle advice and lipid-lowering treatment in the FH cohort was 33 years with 
a 25-percentile of 17 years and a 75-percentile of 47 years. For those who received the FH diagnosis late in life, 
any pre-diagnosis unhealthy lifestyle might have already affected their cancer risk, causing any lifestyle changes 
to have a weaker effect on cancer risk than anticipated. On the other side, it could also be that favorable diet and 
lifestyle changes are not easier to comply with for individuals with FH than controls.
The relationship between statins and cancer has earlier been subject to some debate, especially in the media 
where negative statin-related news stories have resulted in reduced use of statins in some hypercholesterolemic 
individuals and accordingly increased risk of CVD21. A recent summary of several large randomized controlled tri-
als (RCTs) state that there is no association between statins and the risk of cancer22. Yet, studies on very long-term 
exposure to statins are challenging to conduct. Large metaanalyses of RCTs can provide solid evidence but not for 
a longer exposure than the typical duration of RCTs of five years or less23. Development of NCDs like cancer and 
CHD are slow processes24 and data on very long time exposure are sparse. In a subsample (n = 714) of the current 
FH population 89% (n = 635) used statins and mainly potent statins in maximal dose. Mean duration of treatment 
was of 13.5 years18. The corresponding duration of statin treatment were mean 11.9 and 16.1 years for normal risk 
and very high-risk patients, respectively18. The median follow-up time of all individuals with FH in the present 
study was 12.2 years and the maximum follow-up time was 25 years (from 1992 to 2017). As statins usually are 
recommended from the time of FH diagnosis, this supports that the current FH population is likely to have been 
exposed to statins for a considerably longer time than RCTs usually lasts23. In secondary analysis we divided the FH 
population in two, those diagnosed in 1999 or earlier (n = 1104) and those diagnosed in 2000 or later (n = 4417). 
Compared with matched controls, HR for the FH cohort diagnosed before or equal to 1999 was 0.97 (95% CI, 0.79–
1.19) and for those diagnosed in 2000 or later, the HR was 0.97 (95% CI, 0.84–1.12). Since statins were approved in 
1992, the period 1992–1999 reflects possible long time use of statins compared to the period after 1999. Hence, this 
study could support the growing amount of evidence stating that use of statins does not increase the risk of cancer.
Strengths of the present study include the large cohort of genetically verified FH and matched controls and 
the long follow-up time. Since the FH mutation is inherited randomly from heterozygous parents across socio-
economic strata, there is no need to adjust for socioeconomic status. Furthermore, the use of population-based 
registries for collection of endpoints ensured almost no loss to follow-up. The inclusion of data from the NCoDR 
in addition to the CRN, allowed us to take into account deaths as competing events and hence, strengthen our 
results of the observed cancer risk in the FH population. The number of person years of follow-up was 71253, 
which is more than any other study investigating cancer risk in individuals with genetically verified FH.
Limitations include lack of information on medication use including statins, smoking prevalence and fre-
quency, dietary habits, physical activity and other lifestyle factors, and biochemical measures such as LDL-C 
concentration in the study populations. There were few cancer events in FH group overall (n = 289). A greater 
number of FH patients or more events in the FH population are therefore likely to increase the precision of the 
results by reducing the wide CI observed for subgroups within the different lifestyle-related cancer sites. The FH 
population is likely to be more regularly followed up by physicians compared with the control population, which 
could cause cancer to be more easily detected in the FH population. This kind of detection bias would bias the 
incidence of cancer in the FH population upwards and cannot explain why we found a significantly lower risk of 
smoking-related cancer compared with the control population. It could, however, potentially explain why there 
was no difference in risk of cancer related to poor diet. Additionally, there might be limitations regarding the 
individuals who gives their consent to be registered in the UCCG Registry of genetically verified FH, and as only 
about 1/3 (n = 8511) of all individuals assumed to have FH in Norway (~25000) are diagnosed, the current sam-
ple might not reflect the total FH population in Norway9. The low reservation rate (2.5%) to the study however 
strengthens the representativeness of the results.
conclusion
In summary, a FH mutation and corresponding treatment was associated with reduced risk of smoking-related 
cancer in a FH population compared with matched controls, most likely due to a lower prevalence of smoking 
in the FH population. There was no difference in the risk of total cancer and cancer related to poor diet, phys-
ical inactivity, alcohol intake, and body fatness and weight gain between the FH population and the control 
population.
Data availability
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